Recent Quotes
My Watchlist
Indicators
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioAge Labs, Inc. - Common Stock (NQ:BIOA)

7.550 +0.060 (+0.80%)
Streaming Delayed Price Updated: 12:48 PM EST, Nov 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 38,453
Open 7.520
Bid (Size) 7.540 (200)
Ask (Size) 7.580 (300)
Prev. Close 7.490
Today's Range 7.420 - 7.570
52wk Range 2.880 - 22.91
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BioAge Labs to Present at Jefferies Global Healthcare Conference in London
From BioAge Labs, Inc.
Via GlobeNewswire
BioAge Labs Inc (NASDAQ:BIOA) Reports Q3 2025 Earnings with Significant Revenue Beat
BioAge Labs reported a mixed Q3 2025, beating revenue estimates by 94% with a narrower EPS loss. The clinical-stage biotech advanced its lead drug, BGE-102, with cash runway through 2029. 
Via Chartmill

Performance

YTD
+35.8%
+35.8%
1 Month
+37.3%
+37.3%
3 Month
+74.0%
+74.0%
6 Month
+85.5%
+85.5%
1 Year
-66.7%
-66.7%

More News

Read More
BioAge Labs Reports Third Quarter 2025 Financial Results and Provides Business Updates
From BioAge Labs, Inc.
Via GlobeNewswire
Citigroup Says This Obesity Drugmaker's Stock Is Now a Buy
Via The Motley Fool
Could This Anti-Obesity Drug Biotech Be Poised to Soar in 2026?
Via The Motley Fool
BioAge Labs Stock Just Soared. Does It Have More Fuel to Climb Higher?
Via The Motley Fool
Here are the top movers in Thursday's session.
Via Chartmill
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Which stocks are moving on Thursday?
Via Chartmill
These stocks are gapping in today's session
Via Chartmill
Wondering what's happening in today's pre-market session?
Via Chartmill
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
This Badger Meter Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday
Via Benzinga
BIOAGE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into BioAge Labs, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
BioAge Labs to Present at Upcoming Investor Conferences
From BioAge Labs, Inc.
Via GlobeNewswire
BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor
From BioAge Labs, Inc.
Via GlobeNewswire
BioAge Labs (BIOA) Q2 Revenue Hits $2.4M
Via The Motley Fool
Topics Intellectual Property
BioAge Labs Reports Second Quarter 2025 Financial Results and Provides Business Updates
From BioAge Labs, Inc.
Via GlobeNewswire
BIOAGE ALERT: Bragar Eagel & Squire, P.C. is Investigating BioAge Labs, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions
From BioAge Labs, Inc.
Via GlobeNewswire
BioAge Labs Expands Drug Discovery Platform with Data from Leading European Biobank
From BioAge Labs, Inc.
Via GlobeNewswire
BioAge Expands APJ Agonist Pipeline with Oral Small-Molecule and Long-Acting Biologic Candidates
From BioAge Labs, Inc.
Via GlobeNewswire
BioAge Labs completes IND-enabling studies for BGE-102, a potent, orally available, brain-penetrant NLRP3 inhibitor, and advances candidate toward the clinic
From BioAge Labs, Inc.
Via GlobeNewswire
BioAge Labs to Present at Upcoming Investor Conferences
From BioAge Labs, Inc.
Via GlobeNewswire
BIOAGE ALERT: Bragar Eagel & Squire, P.C. is Investigating BioAge Labs, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire

Frequently Asked Questions

Is BioAge Labs, Inc. - Common Stock publicly traded?
Yes, BioAge Labs, Inc. - Common Stock is publicly traded.
What exchange does BioAge Labs, Inc. - Common Stock trade on?
BioAge Labs, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for BioAge Labs, Inc. - Common Stock?
The ticker symbol for BioAge Labs, Inc. - Common Stock is BIOA on the Nasdaq Stock Market
What is the current price of BioAge Labs, Inc. - Common Stock?
The current price of BioAge Labs, Inc. - Common Stock is 7.550
When was BioAge Labs, Inc. - Common Stock last traded?
The last trade of BioAge Labs, Inc. - Common Stock was at 11/11/25 12:48 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.